

Tumor Experience

| Cancer | Phase | # of Patients | # of Sites | Year Started | Year Completed |
|---|--------------|---------------|------------|--------------|----------------|
| AML | II | 40 | 5 | 2001 | 2003 |
| Breast--1 st line Met | IV | 300 | 70 | 2001 | 2004 |
| Breast--1 st line Met | II | 51 | 21 | 2003 | 2007 |
| Breast--1 st line Met | II | 72 | 29 | 2005 | 2008 |
| Breast--Adjuvant ER+ | III | 117 | 8 | 2006 | 2008 |
| Breast--2 nd line Met | III | 7 | 3 | 2006 | 2008 |
| Breast--1 st line Met | III | 17 | 7 | 2006 | 2007 |
| Breast--1 st line Met | II | 16 | 15 | 2007 | 2008 |
| Breast--1 st line Met | II | 32 | 14 | 2008 | Ongoing |
| Breast--1 st /2 nd line Met | II | 5 | 5 | 2008 | 2009 |
| Breast--Adjuvant | IV | 49 | 9 | 2008 | 2009 |
| Breast--1 st /2 nd line Erb2+ | II | 10 | 9 | 2008 | Ongoing |
| Breast--2nd line ER+ | III | 0 | 7 | 2009 | Pending |
| Breast--1st line HER+ | III | 4 | 8 | 2009 | Pending |
| Ovarian--2nd Line | II | 4 | 5 | 2008 | 2009 |
| NSCLC | II b | 110 | 20 | 2003 | 2005 |
| Lung | Epidemiology | 3000 | 65 | 2006 | Ongoing |
| NSCLC--1 st line | II | 82 | 21 | 2004 | 2008 |
| NSCLC--2 nd line | II | 7 | 9 | 2004 | 2006 |
| NSCLC--1 st line | II | 69 | 22 | 2005 | 2007 |
| NSCLC--2 nd line | II | 70 | 15 | 2005 | 2007 |
| NSCLC--1 st line | III | 15 | 4 | 2006 | 2008 |
| NSCLC--Advanced | II | 10 | 8 | 2007 | 2008 |
| NSCLC--1 st line | II | 83 | 18 | 2006 | Ongoing |
| NSCLC--2 nd /3 rd line | III | 10 | 8 | 2007 | Ongoing |
| NSCLC--2 nd line | III | 7 | 9 | 2008 | Ongoing |
| NSCLC--1st line | III | 0 | 3 | 2009 | Pending |
| NSCLC--1st line | III | 0 | 11 | 2009 | Ongoing |
| NSCLC--1st line | III | 32 | 15 | 2009 | Ongoing |
| NSCLC--2 nd line | III | 14 | 9 | 2009 | Ongoing |
| NSCLC-1 st line with Radiation | III | 0 | III | 2009 | Ongoing |
| NSCLC -- 1 st line | III | 11 | 8 | 2008 | Ongoing |
| SCLC--2 nd line | III | 36 | 11 | 2008 | Ongoing |
| SCLC--1st line | I | 34 | 14 | 2008 | Ongoing |
| Rectum | II | 87 | 16 | 2003 | 2008 |
| Colorectal--1st line | II | 82 | 19 | 2004 | 2008 |
| Colorectal--1st line | III | 57 | 31 | 2005 | 2007 |
| Colorectal--2nd line | II | 39 | 15 | 2006 | 2007 |
| Colorectal--1st line | IIb | 31 | 9 | 2008 | Ongoing |
| Colorectal--2nd line | II | 2 | 3 | 2008 | Ongoing |
| Colorectal--1st line | II | 6 | 6 | 2008 | 2009 |

| Cancer | Phase | # of Patients | # of Sites | Year Started | Year Completed |
|--|------------------------------|---------------|------------|--------------|----------------|
| Colorectal--1st line | II | 0 | 4 | 2009 | Ongoing |
| Pancreatic--1st line | II | 8 | 20 | 2003 | 2004 |
| Prostate | I a | 65 | 5 | 2008 | 2009 |
| Prostate | IV | 79 | 12 | 2004 | Ongoing |
| Prostate | IV | 160 | 50 | 2003 | 2006 |
| Prostate | Epidemiology | 120 | 1 | 2007 | 2008 |
| Prostate | II a | 80 | 6 | 2007 | Ongoing |
| Prostate | III a | 250 | 50 | 2002 | 2004 |
| HRPC--1 st line | II | 35 | 22 | 2006 | 2008 |
| HRPC--1 st line | III | 11 | 10 | 2007 | 2007 |
| HRPC--2 nd line and beyond | EAP | 40 | 16 | 2007 | 2007 |
| Kidney | I | 10 | 5 | 2004 | 2007 |
| Kidney | Epidemiology | 35 | 1 | 2008 | 2008 |
| Renal cell--1 st line | III | 45 | 8 | 2006 | 2008 |
| Renal cell--1 st line | III | 6 | 6 | 2008 | Ongoing |
| Renal cell--1st line | III | 6 | 3 | 2009 | Ongoing |
| Hodgkin's Lymphoma | I | 18 | 1 | 2006 | Ongoing |
| Hodgkin's Lymphoma | I | 12 | 1 | 2007 | 2009 |
| NHL | III | 320 | 42 | 2007 | 2008 |
| CLL | IV | 210 | 25 | 2007 | 2007 |
| Mantle Cell Lymphoma --2 nd line | II | 8 | 25 | 2008 | Ongoing |
| MDS--1 st line | II | 15 | 13 | 2004 | 2006 |
| MDS--1st line | III | 0 | 5 | 2009 | Ongoing |
| Biliary tract | II | 61 | 6 | 2003 | 2007 |
| Melano-carcinoma | II a | 152 | 2 | 2007 | 2008 |
| Melanoma--1 st line | II | 11 | 5 | 2007 | 2008 |
| Head and Neck | Investigator-initiated study | 75 | 1 | 2007 | Ongoing |
| Glioblastoma | IV | 150 | 12 | 2000 | 2004 |
| Multiple Myeloma--1st line | III | 30 | 17 | 2007 | Ongoing |
| Myeloma | I | 36 | 3 | | Ongoing |
| Myeloma | IV | 550 | 82 | | Ongoing |
| Myeloma | IV | 300 | 60 | 2001 | 2003 |
| Breast, NSCLC, Colon--Supportive care Antiemetic | II | 33/16 | 14 | 2006 | 2007 |
| Breast--Supportive care Bone Mets | III | 3 | 12 | 2006 | 2007 |
| Bone Mets--Supportive care | III | 23 | 8 | 2006 | 2008 |
| NSCLC--Supportive care Cancer Cachexia | II | 50 | 13 | 2008 | Ongoing |